
## Lauren J Rogak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5465840/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2413.	7.4	108
2	The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. Journal of Psychosocial Oncology, 2021, 39, 285-293.	1.2	18
3	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncology, 2020, 6, e193332.	7.1	39
4	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clinical Cancer Informatics, 2020, 4, 947-957.	2.1	97
5	Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 276-285.	4.4	46
6	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. Journal of Clinical Oncology, 2018, 36, 3120-3125.	1.6	45
7	Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. Journal of Patient-Reported Outcomes, 2018, 2, 56.	1.9	4
8	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Human Factors, 2018, 5, e10070.	2.0	20
9	Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. Journal of Cancer Research and Clinical Oncology, 2017, 143, 735-743.	2.5	36
10	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 2017, 3, 1043.	7.1	98
11	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2017, 98, 409-418.	0.8	87
12	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clinical Trials, 2017, 14, 255-263.	1.6	58
13	Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clinical Therapeutics, 2016, 38, 821-830.	2.5	77
14	Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clinical Trials, 2016, 13, 331-337.	1.6	40
15	Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of Thoracic Oncology, 2016, 11, 890-899.	1.1	4
16	Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Supportive Care in Cancer, 2016, 24, 2843-2851.	2.2	28
17	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health and Quality of Life Outcomes. 2016. 14. 24.	2.4	91
18	The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Supportive Care in Cancer, 2016, 24, 3669-3676.	2.2	249

#	Article	IF	CITATIONS
19	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncology, 2015, 1, 1051.	7.1	581
20	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the National Cancer Institute, 2014, 106, dju244-dju244.	6.3	689